<DOC>
	<DOCNO>NCT00003593</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase III trial study effectiveness combination chemotherapy treat child Down syndrome myeloproliferative disorder , acute myelogenous leukemia , myelodysplastic syndrome .</brief_summary>
	<brief_title>Chemotherapy Treating Children With Down Syndrome Myeloproliferative Disorder , Acute Myelogenous Leukemia , Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy reduced-dose induction intensification chemotherapy , term remission rate , disease-free survival rate , acute morbidity mortality , child Down syndrome acute myelogenous leukemia myelodysplastic syndrome . - Define understanding natural history transient myeloproliferative disorder ( TMD ) child Down syndrome . - Determine whether reduction sequelae long-term survivor treatment regimen . - Determine incidence subsequent leukemia patient transient myeloproliferative disorder treat regimen . - Determine predictive risk factor develop subsequent leukemia patient transient myeloproliferative disorder treat regimen . OUTLINE : This multicenter study . - Group I : Patients observe transient myeloproliferative disorder ( TMD ) require intervention . Patients require therapy TMD undergo leukapheresis exchange transfusion 3 consecutive day . If TMD resolve significant organ involvement , patient receive low-dose cytarabine IV continuously day 0-4 . Treatment repeat least every 2 week 4 course . Patients experience recurrence TMD least 8 week resolution refractory disease may proceed group II treatment . - Group II ( close accrual 6/24/04 except patient first enrol group I ) : Patients receive induction therapy comprise cytarabine IV continuously , daunorubicin IV continuously , oral thioguanine twice daily day 0-3 . Treatment repeat every 28 day 4 course . Patients CNS disease diagnosis receive cytarabine intrathecally ( IT ) day 0 . Patients CNS disease diagnosis receive cytarabine IT day 0 , 5 , 7 . If CNS disease persist day 7 , patient receive 6 course cytarabine IT , hydrocortisone IT , methotrexate IT , twice weekly begin day 10 . Patients achieve remission induction therapy receive 2 course intensification therapy , approximately 4 month . During first course , patient receive cytarabine IV 3 hour twice daily day 0 , 1 , 7 , 8 . Patients also receive asparaginase intramuscularly day 1 8 . The second course therapy comprise CNS prophylaxis . Patients CNS disease diagnosis whose CNS disease resolve day 7 induction therapy receive cytarabine IT day 0 , 7 , 14 . Patients persistent CNS disease day 7 induction therapy receive cytarabine IT , hydrocortisone IT , methotrexate IT day 0 , 7 , 14 . Patients follow monthly 18 month , every 3 month 1 year , every 6 month 2.5 year , annually thereafter . PROJECTED ACCRUAL : A total 70 patient acute myeloid leukemia myelodysplastic syndrome accrue study within 3.2 year . A total 88 patient transient myeloproliferative disorder enter remission accrue study within 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytogenetically prove Down Syndrome ( constitutional trisomy 21 ) transient myeloproliferative disorder ( TMD ) , myelodysplastic syndrome ( MDS ) , acute myelogenous leukemia ( AML ) Must confirm bone marrow aspirate , cerebrospinal fluid exam , blood test Trisomy 21 mosaicism allow Group I : Diagnosis TMD patient older 90 day initial presentation Must nonerythroid blast ( amount ) peripheral blood one following : Verification second sample More 5 % bone marrow blast Hepatomegaly and/or splenomegaly Lymphadenopathy Cardiac pleural effusion OR Histologically cytologically proven TMD blast affect organ fluid ( pericardial , pleural , peritoneal ) Bone marrow aspirate require Group II ( close accrual 6/24/04 ) : Diagnosis MDS AML ( except M3 subtype ) patient older 90 day 29 % blast bone marrow ( without history TMD ) , follow histology : Refractory anemia ( RA ) RA excess blast ( RAEB ) RAEB transformation RA ring sideroblast ( RARS ) Primary cytopenia ( later confirm bone marrow aspirate due marrow hypoplasia ) define one following : Absolute neutrophil count less 500/mm^3 Untransfused platelet count le 30,000/mm^3 Untransfused hemoglobin le 8 g/dL The following diagnosis observe : RA mild cytopenias* RARS mild cytopenias* Mild primary cytopenia ( one ) without dysplasia ( confirm hypoplastic bone marrow exam ) NOTE : * Platelet count 30150,000/mm3 , absolute neutrophil count 5001,499/mm3 , hemoglobin great 8 g/dL Granulocytic sarcoma ( chloroma ) , without bone marrow involvement , allow PATIENT CHARACTERISTICS : Age : See Disease Characteristics 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : See Disease Characteristics Renal : Not specify Cardiovascular : Shortening fraction great 27 % echocardiogram* OR Ejection fraction great 47 % radionuclide angiogram* NOTE : *For patient MDS AML ( 2/24/04 , previously diagnose MDS AML close accrual ; MDS AML develop ( secondary TMD ) study enrollment MDS require initial observation [ without subsequent treatment ] allow ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy TMD allow No prior chemotherapy malignancy Endocrine therapy : Concurrent topical inhaled steroid condition allow Radiotherapy : No prior radiotherapy malignancy Surgery : Not specify Other : No prior antileukemic therapy Prior enrollment study TMD allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>